Abstract
Schizophrenia (SZ) is associated with psychotic experiences and cognitive deficits. Therefore, cognitive function is one of the most critical determinants of quality of life in this pathology. Resveratrol has been related to neuroprotective action, but there are no studies evaluating resveratrol in SZ. The objective of this study was to determine the efficacy of resveratrol supplementation on cognition in individuals with SZ. This is a 1-month randomized, double-blind, and controlled trial (NCT 02062190), in which 19 men with diagnosis of SZ, aged 18-65 years, were assigned to a resveratrol supplementation group (200 mg) or placebo group (200 mg), with a 1-month follow-up. Applying a series of cognitive tests assessed neuropsychology performance (Hopkins Verbal Learning Test, Stroop Color and Word Test, and Weschler Adult Intelligence Scale) and Brief Psychiatric Rating Scale assessed psychopathology severity. There were no significant improvement in neuropsychology performance (episodic memory, working memory, attention and concentration capacity, inhibitory control, interference measures, selective attention, and mental flexibility) and psychopathology severity after 1 month of resveratrol supplementation (P > 0.05). In conclusion, we have shown that 1 month of a resveratrol supplementation (200 mg/day) did not improve episodic memory, working memory, attention and concentration capacity, inhibitory control, interference measures, selective attention, and mental flexibility as compared with placebo in patients with SZ.
Highlights
Schizophrenia (SZ) is a severe mental disorder characterized by psychotic experiences, and profound disruptions in thinking, affecting language, perception, and the sense of self [1]
There are no studies evaluating resveratrol in SZ. According to this line of evidence, the objective of this study was to determine the efficacy of resveratrol supplementation on cognition in individuals with SZ
The research participants followed a 1-month resveratrol supplementation program, which was covered by the Public Health Service at the SZ Program of Hospital de Clinicas de Porto Alegre (HCPA), Brazil
Summary
Schizophrenia (SZ) is a severe mental disorder characterized by psychotic experiences, and profound disruptions in thinking, affecting language, perception, and the sense of self [1]. It is one of the most debilitating psychiatric disorders worldwide [2], and it can impair functioning through the loss of an acquired capability to earn a livelihood or the disruption of studies [1]. Potential agents for the specific central executive processes impaired in SZ are deficits in context processing and conflict detection, and deficits in recollection than in familiarity processes These deficits are frequently associated with disruptions in the function or structural integrity of prefrontal cortex, dorsolateral region of prefrontal cortex.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
